Safety and Efficacy of Two Different Concentrations (0.5% and 1%) of Progesterone Topical Gel Compared to Placebo in Patients Diagnosed With Moderate to Severe Dry Eye Syndrome

Dry Eye Disease Clinical Trial

— ProGIFT  

Official title:

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Pro-ocular™ 0.5% and 1% in Patients With Dry Eye Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04645446
• Other study ID #: 049/SI
• Secondary ID: 2019-000747-27
• Status: Completed
• Phase: Phase 2
• Start date: February 18, 2021
• Est. completion date: October 27, 2022

Study information

• Verified date: March 2021
• Source: SIFI SpA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 clinical trial.

The study objective is to evaluate the safety and efficacy of two different concentrations (0.5% and 1%) of progesterone topical gel compared to placebo, when administered twice a day for 3 months (12 weeks) in patients diagnosed with moderate to severe dry eye syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: October 27, 2022
• Est. primary completion date: October 27, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients (male or female) = 18 years of age.

2. Able and willing to provide voluntary written Informed Consent prior to any study related procedure.

3. Patients must be diagnosed with any type of dry eye at least 3 months before screening (Visit 0).

4. Have all the following in the same eye at Visit 0:

• Fluorescein staining (Cornea) on NEI (National Eye Institute) grading scale > 3

• Average Tear Film Break up Time = 5 seconds

• Schirmer Test (without anesthesia) = 1 and < 10mm

5. Be able and willing to follow instructions, including participation in all study assessments and visits, according to the opinion of the investigator.

Exclusion Criteria:

1. Comorbidity with other severe or chronic conditions that in the judgment of the investigator will interfere with study assessment, such as such as glaucoma, active neuronal trigeminal disease, neuralgia.

2. Best corrected visual acuity (BCVA) baseline <20/200.

3. Condition or history other than ocular that, in the opinion of the investigator, may interfere significantly with the patient's participation in the study, such as dementia, psychosis, Parkinson's disease (interference).

4. Patient using a contact ocular lens within 7 days prior to administration of the first dose and not willing to cease using them during all study duration.

5. Female patients who are pregnant, nursing an infant, or planning a pregnancy or lactating at Screening Visit.

6. Females who are of childbearing potential and not taking adequate contraceptive precautions are excluded from the trial. Females of childbearing potential taking acceptable non-hormonal contraceptive precautions can be included (See Note A).

7. Males with partners who are pregnant or lactating or of childbearing potential and are unwilling to use condoms for the duration of the study.

8. A known adverse reaction and/or sensitivity to the study drug or its components.

9. Use of topical ocular cyclosporine, corticosteroids or any other topical anti-inflammatory treatments within 15 days prior to Visit 0 and during all study duration.

10. Routine use (more than twice a week) of a chlorinated swimming pool during the study period

11. Unwilling or unable to cease using during the study period the forbidden medications:

• Any topical ocular ointments or gels

• Topical and systemic glaucoma therapies

• Systemic drugs with anticholinergic activity: anticonvulsants, antihistamines, antipsychotics, antidepressants, antimuscarinics, anti-Parkinson agents, cardiovascular agents (disopyramide), gastrointestinal agents, muscle relaxants, respiratory medications (pseudoephedrine, theophylline)

• Lipidic artificial tears and artificial tears with preservative.

12. Unwilling to cease the use of sunscreen on the forehead or eye area during the study period.

13. Habitual cigarette smokers (tobacco, vapor cigarettes, marijuana), smoking more than 4 cigarettes per day.

14. Participation in another clinical study at the same time as the present and within 30 days prior to Visit 0.

Related Conditions & MeSH terms

• Dry Eye Disease
• Dry Eye Syndromes
• Eye Diseases
• Keratoconjunctivitis Sicca

Intervention

Drug:
• Pro-ocular gel
Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
• Placebo gel
Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months

Locations

Country	Name	City	State
Italy	Ospedale San Marco - Azienda Ospedaliera Universitaria	Catania
Italy	A.O.U. Careggi Firenze - SOD Oculistica	Florence
Italy	Azienda Ospedaliera Universitaria Policlinico G. Martino - UOC di Oftalmologia	Messina
Italy	Ospedale Luigi Sacco Polo Universitario - Oculistica	Milan

Sponsors (1)

Lead Sponsor	Collaborator
SIFI SpA

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Corneal Fluorescein Staining	Mean change from baseline (Visit 1 pre-dose) in corneal fluorescein staining assessed by NEI scale at Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)	Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)
Primary	SANDE questionnaire	Mean change from baseline (Visit 1 pre-dose) in sum of frequency and intensity of dryness/irritation patient feeling assessed by SANDE questionnaire at Week 12 (Day 84) (with LOCF imputation)	Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)
Secondary	Corneal fluorescein staining	Mean change from baseline (Visit 1 pre-dose) in corneal fluorescein staining assessed by NEI scale at Week 12 (Day 84).	Week 12 (Day 84)
Secondary	SANDE questionnaire	Mean change from baseline (Visit 1 pre-dose) in sum of frequency and intensity of dryness/irritation patient feeling assessed by SANDE questionnaire at Week 12 (Day 84).	Week 12 (Day 84)
Secondary	Conjunctival fluorescein staining	Mean change from baseline (Visit 1 pre-dose) in conjunctival fluorescein staining assessed by NEI scale at Week 12 (Day 84) (with LOCF imputation).	Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)
Secondary	Conjunctival fluorescein staining	Mean change from baseline (Visit 1 pre-dose) in conjunctival fluorescein staining assessed by NEI scale at Week 12 (Day 84).	Week 12 (Day 84)
Secondary	Corneal fluorescein staining	Mean change from baseline (Visit 1 pre-dose) in corneal fluorescein staining assessed by NEI scale at Week 2, 4, 8 (Day 14, 28, 56) as intermediate study visits.	Week 2, 4, 8 (Day 14, 28, 56)
Secondary	SANDE questionnaire	Mean change from baseline (Visit 1 pre-dose) in sum of frequency and intensity of dryness/irritation patient feeling assessed by SANDE questionnaire at Week 2, 4, 8, 16 (Day 14, 28, 56,114) as intermediate study visits.	Week 2, 4, 8, 16 (Day 14, 28, 56,114)
Secondary	Conjunctival fluorescein staining	Mean change from baseline (Visit 1 pre-dose) in conjunctival fluorescein staining assessed by NEI scale at Week 2, 4, 8 (Day 14, 28, 56) as intermediate study visits.	Week 2, 4, 8 (Day 14, 28, 56)
Secondary	Non-Invasive Keratograph Tear Film Break Up (NIKBUT) Time (NIKBUT)	Mean change from baseline (Visit 1 pre-dose) in Non-Invasive Keratograph Tear Film Break Up Time (NIKBUT) at each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)].	Week 2, 4, 8, 12 (Day 14, 28, 56, 84)
Secondary	Fluorescein Tear Film Break Up Time (TBUT)	Mean change from baseline (Visit 1 pre-dose) in Fluorescein Tear Film Break Up Time (TBUT) at Week 12 (Day 84).	Week 12 (Day 84)
Secondary	Tear meniscus height (TMH)	Mean change from baseline (Visit 1 pre-dose) in Tear meniscus height (TMH) at each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)].	Week 2, 4, 8, 12 (Day 14, 28, 56, 84)]
Secondary	Schirmer test	Mean change from baseline (Visit 0 Screening) in Schirmer test at Week 4 (Day 28) and at Week 12 (Day 84).	Week 4 (Day 28) and Week 12 (Day 84)
Secondary	Dry Eye-Related Quality-of-Life (DEQS) questionnaire	Impact of dry eye on quality of life by using Dry Eye-Related Quality-of-Life (DEQS) questionnaire.	Each applicable post baseline visit
Secondary	Visual Analogue Scale	Absolute score of each symptom item in Visual Analogue Scale to each post baseline visit.	Each applicable post baseline visit
Secondary	Visual Analogue Scale	Mean change from baseline (Visit 1 pre-dose) in Visual Analogue Scale 7 symptoms items to each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)].	Week 2, 4, 8, 12 (Day 14, 28, 56, 84)
Secondary	Corneal Sensitivity	Mean change from baseline (Visit 1 pre-dose) in Corneal Sensitivity to each applicable postbaseline visit [Week 4, 12 (Day 28, 84)].	Week 4, 12 (Day 28, 84)
Secondary	Slit Lamp Examination	Mean change from baseline (Visit 0 Screening) in Slit Lamp Examination to each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)].	Week 2, 4, 8, 12 (Day 14, 28, 56, 84)